Shots:
- Novartis to acquire Anthos (launched by Blackstone Life Sciences & Novartis in 2019) for ~$3.1B to boosts its cardiovascular portfolio with Anthos’ abelacimab; closing expected in H1’25
- As per the deal, Anthos will receive $925M upfront & is eligible to receive ~$2.15B in regulatory & commercial milestones
- Abelacimab (licensed from Novartis) showed reduced bleeding events in P-II (AZALEA) trial in comparison to SoC oral anticoagulants & is being investigated in 3 ongoing P-III (LILAC-TIMI 76 for atrial fibrillation; ASTER & MAGNOLIA for cancer-associated thrombosis) trials to prevent stroke & systemic embolism
Ref: Novartis | Image: Anthos Therapeutics
Related News:- Dawn Health & Novartis Introduce Cora BC to Support Breast Cancer Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
